Opzelura and Skin hyperpigmentation - a phase IV clinical study of FDA data

Summary:

Skin hyperpigmentation is reported as a side effect among people who take Opzelura (ruxolitinib phosphate), especially for people who are and have Vitiligo.

The phase IV clinical study analyzes which people have Skin hyperpigmentation when taking Opzelura. It is created by eHealthMe based on reports of 1,959 people who have side effects when taking Opzelura from the FDA, and is updated regularly.

What is Opzelura?

Opzelura has active ingredients of ruxolitinib phosphate. eHealthMe is studying from 1,961 Opzelura users. Check the latest studies of Opzelura.

What is Skin hyperpigmentation?

Skin hyperpigmentation (disorders affect the colour of your skin) is found to be associated with 643 drugs and 812 conditions by eHealthMe. Check the latest studies of Skin hyperpigmentation.

On Jul, 28, 2026

1,959 people reported to have side effects when taking Opzelura.
Among them, 15 people (0.77%) have Skin hyperpigmentation.

Could Opzelura cause Skin hyperpigmentation?

Among these 15 people:

What are other side effects people have besides Skin hyperpigmentation? *

Vitiligo (pigment is lost from areas of the skin): 1 person, 6.67%
Visual Impairment: 1 person, 6.67%
Rash Papular (redness with papule): 1 person, 6.67%
Melasma (the mask of pregnancy when present in pregnant women) is a tan or dark skin discoloration): 1 person, 6.67%
Itching: 1 person, 6.67%

What are the existing conditions these people have? *

Vitiligo (pigment is lost from areas of the skin): 14 people, 93.33%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Opzelura and have Skin hyperpigmentation?

- Check whether Skin hyperpigmentation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opzelura:

Opzelura (1,961 reports)

Browse all side effects of Opzelura:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (643 drugs)

Browse all the conditions that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (812 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Opzelura) and Opzelura (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.